2021
Continuation of clinical trials and health interventions with the Abdala vaccine and the Mambisa vaccine candidate against covid-19.
The Center for the State Control of Medicines, Equipment and Medical Devices (CECMED) verified the 92.28% efficacy of Abdala against the symptomatic disease (covid-19).
The Center for the State Control of Medicines, Equipment and Medical Devices (CECMED) decided to grant the Authorization of Emergency Use (AUE) to the Cuban vaccine Abdala 50 µg , in accordance and in observance to the provisions of the regulations and provisions in force, once it has been confirmed that the requirements and parameters demanded in terms of quality, safety and efficacy for this type of procedure are met. Abdala is the first vaccine developed and produced in Latin America and that manages to obtain emergency use.